Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy

Share :
Published: 21 Apr 2022
Views: 101
Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain

Dr Iván Márquez-Rodas speaks to ecancer about the final results of SPOTLIGHT203 phase 2 study.

This study investigates the efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy.

He initially explains about the background and methodology of the study. He says that the analysis showed that the primary endpoint (ORR by independent reviewer) has been met.

Dr Márquez-Rodas points out that with a median follow up of seven months, there is a clear clinical benefit in patients with confirmed anti-PD1-resistant melanoma, with a 25% ORR and a 65% DCR: superior to 2nd line Standard of Care in stage III/IV melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).

He further explains the results by mentioning that three hard-to-treat mucosal melanoma patients achieved an ORR of 66% and DCR of 100%, high baseline LDH levels (>3xULN) from the study predicted progressive disease. He says study treatment has a manageable safety profile, with no patients discontinuing due to adverse events.

Dr Márquez-Rodas concludes by explaining how the results can impact the future treatment of melanoma.